logo

SHILPAMED vs WOCKPHARMA: Stock Comparison

SHILPA MEDICARE vs WOCKHARDTUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. SHILPA MEDICARE shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SHILPAMED leads 9; WOCKPHARMA leads 2 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SHILPAMEDWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹16,892 Cr
₹30,126 Cr
P/E RatioSHILPAMED has the lower reading
56.66x ✓
73.66x
P/B RatioWOCKPHARMA has the lower reading
6.5x
6.1x ✓
EPSWOCKPHARMA has the higher reading
₹5.16
₹6.52 ✓
Book ValueContext only
₹132.49
₹325
Dividend YieldSHILPAMED has the higher reading
0.07% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,126 Cr vs ₹16,892 Cr
P/E Ratio
SHILPAMED has a lower P/E
56.66x vs 73.66x
P/B Ratio
WOCKPHARMA has a lower P/B
6.1x vs 6.5x
EPS
WOCKPHARMA has higher earnings per share
₹6.52 vs ₹5.16
Dividend Yield
SHILPAMED has a higher dividend yield
0.07% vs 0%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs 26%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs 0%
ROE
SHILPAMED has a higher ROE
9.39% vs 3.77%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSHILPAMEDWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSHILPAMEDWOCKPHARMA
Live Price₹860.8₹1,855.5
Day Change1.85%-1.16%
Volume14.95 L4.57 L
52-Week High₹1,095₹2,422.3
52-Week Low₹259.5₹1,086.7
Distance from 52W High-21.39%-23.4%

Valuation

MetricSHILPAMEDWOCKPHARMA
Market Cap₹16,892 Cr₹30,126 Cr
P/E Ratio56.66x73.66x
P/B Ratio6.5x6.1x
EPS₹5.16₹6.52
Book Value₹132.49₹325
Dividend Yield0.07%0%

Growth

MetricSHILPAMEDWOCKPHARMA
Revenue Growth (TTM YoY)31.5%26%
EPS Growth (TTM YoY)644.6%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricSHILPAMEDWOCKPHARMA
ROE9.39%3.77%
ROCE9.1%5.44%
Net Margin15.82%3.3%
Operating Margin23.01%13.37%
Debt to Equity0.25x0.4x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricSHILPAMEDWOCKPHARMA
Promoter Holding40.13%49.08%
FII Holding12.11%▲ 0.73 pp7.22%▲ 0.13 pp
DII Holding8.26%▲ 0.21 pp9.24%▼ 1.72 pp
Public Holding39.49%▼ 0.94 pp34.44%▲ 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHILPA MEDICARE and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.